

At a Glance

- Active since 2004
- Spin-off of the Max Planck Institute of Psychiatry

Management Team

- Alex Martin, CEO
- Luc St-Onge, CBO
- Stephen Murray, CMO
- Michael Bös, CSO
- Inge Sillaber, Behavioural Pharmacology

Supervisory Board

- Joachim Rothe, Chairman
- Domenico Valerio, Vice-Chairman
- Dr. Stefan Herr
- Wolfgang Wurst

Scientific Advisors

- Hanns Möhler, Chairman
- Florian Holsboer (Psychiatry)
- Kay Brune (Pharmacology)
- Francesco DiVirgilio (Inflammation)
- Klaus Wanner (Chemistry)
- Adriaan Sitsen (Clinical trials)

Investors

- Life Sciences Partners
- Aescap Venture
- EMBL Technology Fund
- KfW
- BayernKapital
- Adamant Biomedical Investments

Contact:

Luc St-Onge, CBO
Affectis Pharmaceuticals AG
Fraunhoferstrasse 13
D-82152 Martinsried
Germany
Tel. +49 (0)89 893 2811 100
Fax. +49 (0)89 893 2811 111
info@affectis.com
www.affectis.com

Novel Drugs for the Treatment of Psychiatric and Neuroinflammatory Disorders

Affectis is a biopharmaceutical company developing novel drugs for the treatment of psychiatric and neuroinflammatory disorders.

Affectis' unique capabilities in drug discovery and behavioural pharmacology allow the company to develop drugs with innovative mechanisms of action based on pioneering findings.

Today's psychiatric market is dominated by therapeutic concepts that are decades old. Shortcomings of existing drugs range from delayed onset of action to a significant rate of non-responders and unwanted side effects. Affectis' programs carry the promise of bringing to market entirely new classes of drugs that would address and satisfy unmet needs.

Pipeline

Programs	Indication	Preclinical	Phase I	Phase II	Phase III
Cimicoxib	Depression	▶			
Cimicoxib	Schizophrenia	▶			
AFC-5128 (P2X7 Antagonists)	MS / NP	▶			
AFC-08 (TMEFF2 mAb)	Depression	▶			
Other Targets	Depression	▶			

Psychiatric Programs

Affectis is developing Cimicoxib for the treatment of psychiatric disorders. A phase II trial in depression will be completed in early 2010. Clinical studies will also be initiated in 2010 for schizophrenia. The company is investigating AFC-08, a monoclonal antibody targeting the brain membrane protein TMEFF2 for potential prophylactic and relapse prevention in depression. Affectis is also developing additional targets such as EP1 receptor antagonists which modulate prostaglandin-endocannabinoid signalling in the brain resulting in antidepressant effects.

Neuroinflammation Program

Affectis has identified AFC-5128, a novel brain-penetrant and highly potent oral P2X7 antagonist for the treatment multiple sclerosis (MS), and neuropathic pain (NP). AFC-5128 is currently in preclinical development with IND filing planned for 2010 and initiation of phase I studies shortly thereafter.

Business Model and Collaborations

The Company has the capabilities to move its proprietary drug candidates from discovery to phase II clinical development. At the same time, Affectis is seeking partnerships with pharmaceutical companies to accelerate development and commercialisation of its candidates. Affectis' extensive expertise in behavioural pharmacology has already attracted high-profile parties like Mitsubishi Tanabe Pharma, Novartis, Organon for research agreements involving validation of drug candidates in depression.